- Glaukos Announces Participation in Upcoming Investor Conferences
May 12, 2026 · businesswire.com
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced that its management is scheduled to participate in the following upcoming investor conferences: Stifel Virtual Ophthalmology Forum on Tuesday, May 26, 2026, at 1:30 p.m. ET William Blair 46th Annual Growth Stock Conference on Tuesday, June 2, 2026, at.
- GLAUKOS ANNOUNCES PARTICIPATION IN UPCOMING INVESTOR CONFERENCES
May 12, 2026
ALISO VIEJO, CALIF.--(BUSINESS WIRE)--GLAUKOS CORPORATION (NYSE: GKOS), AN OPHTHALMIC PHARMACEUTICAL AND MEDICAL TECHNOLOGY COMPANY FOCUSED ON NOVEL THERAPIES FOR THE TREATMENT OF GLAUCOMA, CORNEAL DISORDERS, AND RETINAL DISEASES, TODAY ANNOUNCED THAT ITS MANAGEMENT IS SCHEDULED TO PARTICIPATE IN THE FOLLOWING UPCOMING INVESTOR CONFERENCES: STIFEL VIRTUAL OPHTHALMOLOGY FORUM ON TUESDAY, MAY 26, 2026, AT 1:30 P.M. ET WILLIAM BLAIR 46TH ANNUAL GROWTH STOCK CONFERENCE ON TUESDAY, JUNE 2, 2026, AT.
- Glaukos Gains on Q1 Earnings Beat & Improved 2026 Revenue Outlook
Apr 30, 2026 · zacks.com
GKOS beats Q1 estimates with 41% revenue growth, narrows loss and raises 2026 outlook as glaucoma and corneal segments drive momentum.
- Glaukos Corporation (GKOS) Q1 2026 Earnings Call Transcript
Apr 29, 2026 · seekingalpha.com
Glaukos Corporation (GKOS) Q1 2026 Earnings Call Transcript
- Glaukos (GKOS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Apr 29, 2026 · zacks.com
While the top- and bottom-line numbers for Glaukos (GKOS) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
- Glaukos (GKOS) Reports Q1 Loss, Tops Revenue Estimates
Apr 29, 2026 · zacks.com
Glaukos (GKOS) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.3. This compares to a loss of $0.22 per share a year ago.
- Glaukos Announces First Quarter 2026 Financial Results
Apr 29, 2026 · businesswire.com
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced financial results for the first quarter ended March 31, 2026. Key highlights include: Record net sales of $150.6 million in Q1 2026 increased 41% year-over-year on a reported basis and 39% year-over-year on a constant currency basis. Glaucoma record ne.
- GLAUKOS ANNOUNCES FIRST QUARTER 2026 FINANCIAL RESULTS
Apr 29, 2026
ALISO VIEJO, CALIF.--(BUSINESS WIRE)--GLAUKOS CORPORATION (NYSE: GKOS), AN OPHTHALMIC PHARMACEUTICAL AND MEDICAL TECHNOLOGY COMPANY FOCUSED ON NOVEL THERAPIES FOR THE TREATMENT OF GLAUCOMA, CORNEAL DISORDERS, AND RETINAL DISEASES, TODAY ANNOUNCED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2026. KEY HIGHLIGHTS INCLUDE: RECORD NET SALES OF $150.6 MILLION IN Q1 2026 INCREASED 41% YEAR-OVER-YEAR ON A REPORTED BASIS AND 39% YEAR-OVER-YEAR ON A CONSTANT CURRENCY BASIS. GLAUCOMA RECORD NE.
- Glaukos Wins Permanent J-Code for Epioxa Keratoconus Therapy
Apr 16, 2026 · zacks.com
GKOS secures a permanent CMS J-code for Epioxa, a move set to streamline reimbursement and expand patient access in keratoconus treatment.
- Glaukos Announces the Release of its 2025 Sustainability Report
Apr 16, 2026 · businesswire.com
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced that it has published its 2025 Sustainability Report. The report highlights the company's continued commitment and progress on its key corporate sustainability priorities. The Sustainability Report can be found on the company's website here. “I am prou.